Hirt Déborah, Urien Saik, Rey Elisabeth, Arrivé Elise, Ekouévi Didier K, Coffié Patrick, Leang Sim Kruy, Lalsab Sarita, Avit Divine, Nerrienet Eric, McIntyre James, Blanche Stéphane, Dabis François, Tréluyer Jean-Marc
EA3620, Université Paris-Descartes, Paris, France.
Antimicrob Agents Chemother. 2009 Mar;53(3):1067-73. doi: 10.1128/AAC.00860-08. Epub 2008 Dec 22.
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters x h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg x liter(-1) x h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg x liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.
本研究的目的是评估孕妇及其新生儿中恩曲他滨(FTC)的药代动力学,并确定新生儿出生后预防人类免疫缺陷病毒(HIV)母婴传播的最佳预防剂量。共有38名感染HIV的孕妇在分娩开始时服用替诺福韦酯(300mg)-FTC(200mg)片剂两片,产后每天一片,共服用7天。通过配对,使用经过验证的高效液相色谱-串联质谱法测量11对母婴、1份脐血和2份新生儿FTC浓度,并采用群体方法进行分析。模型和均值估计(个体间变异性)显示,母亲的药代动力学模型为二室模型,吸收速率常数为0.54 h⁻¹(61%),表观消除率和隔室间清除率分别为23.2(17%)和6.04升·h⁻¹,表观中央室和外周室容积分别为127升和237升;脐血的效应室与母体循环相关,新生儿室在分娩后断开连接,半衰期为10.6小时(30%)。给予400mg FTC后,孕妇群体浓度-时间曲线下面积的中位数以及血浆FTC的最小和最大浓度分别为14.3mg·升⁻¹·h、1.68mg/升和0.076mg/升。分娩时,预测的母体和脐血FTC浓度中位数(范围)分别为1.16(0.14至1.99)mg·升⁻¹和0.72(0.05至1.19)mg·升⁻¹。我们得出结论,在稳态下,孕妇服用400mg FTC比其他成年人服用200mg时的暴露量更高。FTC显示出良好的胎盘转运(80%)。出生后尽快给予1mg FTC/kg或出生12小时后给予2mg/kg应能使新生儿体内的浓度与成年人中观察到的浓度相当。